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vanced Sterilization Products.In the United States in 2010, there were approximately 51.4 million
inpatient surgical procedures and an even larger number of invasive
medical procedures performed.1 For example, there were over
6.9 million upper gastrointestinal (GI), 11.5 million lower GI, and
228,000 biliary endoscopies performed in 2009.2 Each of these pro-
cedures involves contact by a medical device or surgical instrument
with a patient’s sterile tissue or mucous membranes. A major risk of
all such procedures is the introduction of pathogenic microbes,
which can lead to infection. Failure to properly disinfect or sterilize
equipment may lead to transmission via contaminated medical and
surgical devices (eg, carbapenem-resistant Enterobacteriaceae [CRE]).3,4
Multiple studies in many countries have documented lack of com-
pliance with established guidelines for disinfection and sterilization.5
Failure to comply with scientifically-based guidelines has led to
numerous outbreaks and patient exposures.6 In fact, nearly all infec-
tions and patient exposures associated with reprocessing medical or
surgical instruments involve high-level disinfection (HLD) of reusable
semicritical items.6−8 Because of noncompliance with recommended
reprocessing procedures, the Centers for Disease Control and Preven-
tion (CDC) and the Food and Drug Administration (FDA) issued a
health advisory alerting health care providers and facilities about the
public health need to properly maintain, clean, disinfect, and sterilize
reusable medical devices in September 2015.9 In this expanded and
updated version of a previous article on this subject,10,11 we willexamine outbreaks associated with semicritical items and current
issues associated with reprocessing semicritical items. Because semi-
critical items carry the greatest risk of infection we also will discuss
reprocessing semicritical items such as: GI endoscopes and broncho-
scopes, nasal endoscopes, endocavitary probes, transrectal ultra-
sound-guided prostate biopsy probes, tonometers, laryngoscopes,
transesophageal echocardiogram (TEE) probes, infrared coagulation
devices, and urologic instruments (eg, cystoscopies, ureteroscopes).
A RATIONAL APPROACH TO DISINFECTION AND STERILIZATION
Approximately 50 years ago, Earle H. Spaulding12 devised a rational
approach to disinfection and sterilization of patient-care items or
equipment. This classification scheme is so clear and logical that it has
been retained, refined, and successfully used by infection control pro-
fessionals and others when planningmethods for disinfection or sterili-
zation.13−18 Spaulding believed that the nature of disinfection could be
understood more readily if instruments and items for patient care were
divided into 3 categories, based on the degree of risk of infection
involved in the use of the items. The 3 categories he described were
critical (enters sterile tissue and must be sterile), semicritical (contacts
mucous membranes and requires HLD), and noncritical (contact with
intact skin and requires low-level disinfection). Although the scheme
remains valid there are some examples of disinfection studies with
viruses, mycobacteria, and protozoa that challenge the current defini-
tions and expectations of high- and low-level disinfection.19
SEMICRITICAL ITEMS
Semicritical items are those that come in contact with mucous
membranes or nonintact skin. Respiratory therapy and anesthesia
Table 1
Summary of advantages and disadvantages of chemical agents used as chemical sterilants or as high-level disinfectant/chemical sterilant*
Sterilization method Advantages Disadvantages
Peracetic acid/hydrogen
peroxide
 No activation required Material compatibility concerns (lead, brass, copper, zinc)
both cosmetic and functional
 Limited clinical experience
Mucous membrane and respiratory health effects
 Potential for eye and skin damage
Glutaraldehyde  Numerous use studies published
 Relatively inexpensive
 Excellent material compatibility
 Respiratory irritation from glutaraldehyde vapor
 Pungent and irritating odor
 Relatively slow mycobactericidal activity (unless other dis-
infectants added such as phenolic, alcohol)
 Coagulates blood and fixes tissue to surfaces
 Allergic contact dermatitis
 ACGIH recommends limiting employee exposure to ceiling
concentration of 0.05 ppm
Hydrogen peroxide
(standard)
 No activation required
May enhance removal of organic matter and organisms
 No disposal issues
 No odor or irritation issues
 Does not coagulate blood or fix tissues to surfaces
 Inactivates Cryptosporidium at 6%-7.5%
 Use studies published
Material compatibility concerns (brass, zinc, copper, and
nickel/silver plating) both cosmetic and functional
 Serious eye damage with contact
OPA  Fast acting high-level disinfectant
 No activation required
 Odor not significant
 Excellent materials compatibility claimed
 Does not coagulate blood or fix tissues to surfaces claimed
 Relatively rapid mycobactericidal activity
 Stains protein gray (eg, skin, mucous membranes, clothing,
and environmental surfaces)
More expensive than glutaraldehyde
 Eye irritation with contact
 Slow sporicidal activity
 Anaphylactic reactions to OPA in bladder cancer patients
with repeated exposure to OPA through cystoscopy
Peracetic acid  Standardized cycle (eg, liquid chemical sterilant processing system
using peracetic acid, rinsed with extensively treated potable water)
 Low temperature (50°C-55°C) liquid immersion sterilization
 Environmental friendly by-products (acetic acid, O2, H20)
 Fully automated
 Single-use system eliminates need for concentration testing
May enhance removal of organic material and endotoxin
 No adverse health effects to operators under normal operating con-
ditions
 Compatible with many materials and instruments
 Does not coagulate blood or fix tissues to surfaces
 Sterilant flows through scope facilitating salt, protein, and microbe
removal
 Rapidly sporicidal
 Provides procedure standardization (constant dilution, perfusion of
channel, temperatures, exposure)
 Potential material incompatibility (eg, aluminum anodized
coating becomes dull)
 Used for immersible instruments only
 Biological indicator may not be suitable for routine
monitoring
 One scope or a small number of instruments can be
processed in a cycle
More expensive (endoscope repairs, operating costs,
purchase costs) than HLD
 Serious eye and skin damage (concentrated solution) with
contact
 Point-of-use system, no sterile storage
 An AER using 0.2% peracetic acid not FDA-cleared as




 No activation required
 No odor
 Nonstaining
 No special venting requirements
Manual or automated applications
 12 month shelf life, 14 day reuse
 8 min at 20°C high-level disinfectant claim
Material compatibility concerns because of limited clinical
experience
 Organic material resistance concerns because of limited data
All products effective in presence of organic soil, relatively easy to use, and have a broad spectrum of antimicrobial activity (bacteria, fungi, viruses, bacterial spores, and mycobacte-
ria). The characteristics in the Table are documented in the literature; contact the manufacturer of the instrument and HLD/chemical sterilant for additional information. All prod-
ucts listed in the Table are FDA-cleared as chemical sterilants except OPA and 2% accelerated hydrogen peroxide, which are FDA-cleared high-level disinfectants.
ACGIH, American Conference of Governmental Industrial Hygienists; AER, automated endoscope reprocessor; FDA, Food and Drug Administration; HLD, high-level disinfection; OPA,
ortho-phthalaldehyde.
*Modified from Rutala andWeber10,11,13-17equipment, GI endoscopes, bronchoscopes, laryngoscopes, TEE probes,
tonometers, endocavitary probes, transrectal ultrasound-guided pros-
tate biopsy probes,20 cystoscopes, hysteroscopes, infrared coagulation
devices, and diaphragm fitting rings are included in this category. These
medical devices should be free of all microorganisms (ie, mycobacteria,
fungi, viruses, and bacteria), although small numbers of bacterial spores
may be present. Intact mucous membranes, such as those of the lungs
or the GI tract, generally are resistant to infection by common bacterial
spores but susceptible to other organisms such as bacteria, mycobacte-
ria, and viruses. Semicritical items minimally require HLD using
chemical disinfectants. Glutaraldehyde, hydrogen peroxide, ortho-
phthalaldehyde (OPA), peracetic acid, peracetic acid with hydrogenperoxide, and a chlorine-based system are cleared by the FDA21 and are
dependable high-level disinfectants provided the factors influencing
germicidal procedures are met. Table 1 lists the FDA-cleared high-level
disinfectants and chemical sterilants with the advantages and disad-
vantages of each. The exposure time for most high-level disinfectants
varies from 8-45 minutes at 20°C-25°C.21 As with all medications and
devices, users must be familiar with the manufacturer’s instructions for
use (IFU). When a disinfectant is selected for use with certain patient-
care items, the chemical compatibility after extended use with the
items to be disinfected also must be considered. Disinfection strategies
for some semicritical items (eg, applanation tonometers, rectal/vaginal
probes) are highly variable.22
Table 2






Vaginal probes 0** 0









Transesophageal echocardiogram 551,54-57 0
Applanation tonometers 241,42
GI endoscopes/bronchoscopes »1307,8 3 HBV34; HCV35,36
GI, gastrointestinal; HBV, hepatitis B virus; HCV, hepatitis C virus.
*These infections/outbreaks were found in the peer-review literature through PubMed
and Google.
**Does not include outbreaks associated with contaminated ultrasound gel used with
vaginal probes or transmission via health care personnel.Because semicritical equipment has been associated with reproc-
essing errors that result in patient look-back and patient notifications,
it is essential that control measures be instituted to prevent patient
exposures.6 Before new equipment (especially semicritical equip-
ment as the margin of safety is less than that for sterilization)23 is
used for patient care on more than 1 patient, reprocessing procedures
for that equipment should be developed. The FDA requests that the
device manufacturer include at least 1 validated cleaning and disin-
fection and sterilization protocol in the labeling for their device. Staff
should receive training on the safe use and reprocessing of the equip-
ment and be competency tested. At the University of North Carolina
Hospitals, to ensure patient-safe instruments, all staff that reprocess
semicritical instruments (eg, instruments that contact a mucous
membrane such as vaginal probes, endoscopes, prostate probes) are
required to attend a 3-hour class on HLD of semicritical instruments
initially and a 1-hour refresher class annually. The 3-hour class
includes the rationale for and importance of HLD, discussion of high-
level disinfectants and exposure times, reprocessing steps, monitor-
ing minimum effective concentration, personal protective equipment,
and the reprocessing environment (establish “dirty-to-clean” flow).
Infection control rounds or audits should be conducted at least annu-
ally in all clinical areas that reprocess critical and semicritical devices
to ensure adherence to the reprocessing guidelines, manufacturers’
instructions-for-use, and institutional policies. This includes reproc-
essing critical and semicritical medical and surgical instruments in
outpatient care facilities as many patient exposures and infections
have occurred in this setting.24 Results of infection control rounds
should be provided to the unit managers and deficiencies in reproc-
essing should be corrected and the corrective measures documented
to infection control within 30 days. Patient safety issues such as the
wrong contact time, temperature, or concentration of high-level dis-
infectant require immediate correction.
Semicritical items that will have contact with mucous membranes
of the GI tract or upper respiratory tract should be rinsed with sterile
water or filtered water or tap water followed by an alcohol rinse.17,25
An alcohol rinse and forced-air drying markedly reduces the likeli-
hood of contamination of the instrument (eg, endoscope), most likely
by removing the wet environment favorable for bacterial growth.26
After rinsing, items should be dried and stored in a manner that pro-
tects them from damage or contamination. Drying also retards bio-
film formation.27 There is no recommendation to use sterile or
filtered water rather than tap water for rinsing semicritical equip-
ment that will have contact with the mucous membranes of the rec-
tum (eg, rectal probes, anoscope) or vagina (eg, vaginal probes).17
Semicritical items represent the greatest risk of disease transmis-
sion as far more health care−associated infections have been caused
by reusable semicritical items than critical or noncritical items.11
There is virtually no documented risk of transmitting infectious
agents to patients via noncritical items28 when they are used as non-
critical items and do not contact nonintact skin and/or mucous mem-
branes. Similarly, critical items are rarely29 associated with disease
transmission. In contrast, semicritical items (eg, GI endoscopes), by
virtue of the body cavities they enter, may contain 107-10 (7-10-log10)
enteric microorganisms.30,31 Investigations have demonstrated that
the cleaning step in endoscope reprocessing results in a 2-6-log10
reduction of microbes and the HLD step results in another 4-6-log10
reduction of mycobacteria for a total 6-12-log10 reduction of
microbes.30−32 Thus, the margin of safety associated with cleaning
and HLD of GI endoscopes is minimal or nonexistent (level of contam-
ination: 4-log10 [maximum contamination, minimal cleaning/HLD]
to −5-log10 [minimum contamination, maximum cleaning/HLD]).23
Therefore, any deviation from proper reprocessing (such as crevices
associated with the elevator channel) could lead to failure to elimi-
nate contamination with a possibility of subsequent patient-to-
patient transmission. This low (or nonexistent) margin of safetyassociated with endoscope reprocessing compares to the 17-log10
margin of safety associated with cleaning and sterilization of surgical
instruments.23 This is the reason that semicritical items represent the
greatest risk of disease transmission via a reusable medical or surgical
instrument and critical items are rarely29 associated with infection.OUTBREAKS
Transmission of infections (and bloodborne pathogens) associated with
the use of semicritical medical devices
GI endoscopes and bronchoscopes have been associated with far
more outbreaks of infections (>130 outbreaks) than any other reus-
able medical or surgical device in health care.7,8 Other semicritical
items (eg, urologic instruments, TEE probes) have also been associ-
ated with outbreaks of infection. To assess the frequency of infec-
tions/outbreaks associated with all semicritical medical devices
(Table 2), a systematic review of the literature was conducted.33 The
databases used were PubMed and Google and the search terms and
subject heading terms were: hepatitis, hepatitis B virus (HBV), hepati-
tis C virus (HCV), human immunodeficiency virus (HIV), endoscopes,
medical devices, semicritical medical items, vaginal probes, nasal
endoscopes, hysteroscopes, urologic instruments, GI endoscopes,
bronchoscopes, transrectal-ultrasound guided prostate probe, appla-
nation tonometers, TEE, infrared coagulation, infection, and out-
breaks. The reference lists of articles retrieved were also searched for
relevant articles. There was no language restriction; articles were
evaluated for inclusion when an English translation of the article or
abstract was available. Abstracts from scientific meetings were not
included.
HCV and HBV transmission during endoscopy and use of semicriti-
cal medical devices can occur, but it is rare. Three reports related to
breaches in semicritical device reprocessing were found involving
HBV and HCV, and all involved GI endoscopes.34−36 There is 1 report
of HBV transmission via GI endoscopy34 and 2 reports of HCV trans-
mission associated with GI endoscopes.35,36 In general, transmission
of HBV and HCV in health care in the United States is uncommon and
typically associated with unsafe injection practices.37 No articles
relating to possible transmission of HIV via medical instruments,
including semicritical medical devices, were identified. The articles
for HBV and HCV transmission associated with GI endoscopes were
written prior to the comprehensive endoscope reprocessing guide-
lines that are now available.
There are limitations to this type of review. For example, only
published literature was included, and it is more likely that instances
of transmission were published than instances of nontransmission.
This would likely overestimate the frequency of transmission. In
contrast, many outbreaks go undetected and almost certainly out-
breaks associated with semicritical medical devices have gone unre-
ported. For example, most persons with incident HCV and HBV
infections are asymptomatic. Even when symptomatic persons are
identified, many hospitals and health departments do not have the
resources to thoroughly investigate all individuals with HBV or
HCV.38 We have the greatest risk of transmission associated with GI
endoscopes and bronchoscopes owing to the high microbial load in
GI endoscopes (107-1010 in internal channels of a GI endoscope) and
complexity of the instrument. The microbial load associated with a
vaginal probe, nasal endoscopes, and cystoscopes is thought to be
less owing to the presence of fewer organisms at those sites (eg,
vagina, oropharynx [101-105/mL in nasal washings], urinary tract)
compared to the GI tract (109-1012/mL in the colon). Additionally,
endoscopic instruments with channels may allow the development
of biofilms when the instruments are not completely dry.23,27 For
these reasons, there are over 130 reported outbreaks of infections
associated with GI endoscopes and bronchoscopes. Many of these
outbreaks were related to breeches in endoscope reprocessing
(eg, inadequate cleaning, disinfection, and drying procedures) but
between 2012 and spring 2015, closed-channel duodenoscopes
were linked to at least 25 different outbreaks of multidrug-resistant
organisms (MDROs) that sickened at least 250 patients worldwide.8
Since 2010, there have been at least 9 outbreaks of duodenoscope-
related infections of MDROs without reprocessing breaches. In these
outbreaks, the CDC and/or other investigators monitored endoscope
reprocessing procedures and concluded they were compliant
with the manufacturer’s IFU and professional organizational
recommendations.39
Transmission of bloodborne pathogens (BBP) (ie, HBV, HCV, HIV)
or other infectious agents related to improper reprocessing of a vagi-
nal probe have not been documented. In addition, there are no out-
breaks of BBP, or other infections related to lapses in reprocessing of
nasal endoscopes and hysteroscopes. Outbreaks associated with the
use of vaginal probes have occurred but they have involved the use of
a contaminated ultrasound gel or noncompliance with the manufac-
turer’s IFU.33 There has been 1 outbreak associated with the transrec-
tal-ultrasound guided prostate probe,40 2 outbreaks associated with
applanation tonometers.41,42 and at least 2 outbreaks connected to
laryngoscopes.43−45
Eight outbreaks that involved urologic instruments and reprocess-
ing failures were identified. None of those outbreaks involved trans-
mission of BBP such as HIV, HBV and HCV.46−53 The lapses in
reprocessing included: inadequate camera head cleaning;47 improper
cleaning and disinfecting cystoscopes for >10 years;49 incomplete
cleaning and disinfection of the cystoscope;48 and incorrect cysto-
scope reprocessing.46
Transmission of BBP related to improper reprocessing of a TEE
probe has not been documented; however, 5 outbreaks of infection
have occurred associated with the use of TEE probes.51,54−57 The out-
breaks were associated with a damaged or defective probe;54,55 non-
compliance with reprocessing procedure;56 and the use of a TEE
probe rinsed with contaminated water.57 Outbreaks associated with
contaminated ultrasound gel in multiuse bottles used for TEE and
other endocavitary probe procedures are not included as they do not
represent failure of disinfection, but rather intrinsic or extrinsic con-
tamination of the gel. Recommendations for minimizing the health
risks of using gels involve use of single-use, sterile gels for invasive
procedures that pass through a tissue, for all studies involving neo-
nates, for all procedures involving sterile equipment or nonintact
skin, and for procedures on intact mucous membranes.58A look-back or exposure investigation of patients potentially exposed to
BBP via medical instruments
When there is a failure to follow reprocessing guidelines for semi-
critical items, health care facilities should assess the risk of exposed
patients to BBP using a 14-step protocol.6 On occasion, health care
facilities have considered evaluating exposed patients for not only for
BBP but also for other epidemiologically important pathogens such as
multidrug resistant Enterobacteriaceae or C difficile. Regarding an epi-
demiologic look-back investigation (ie, systematic notification of
patients by health care facilities) for transmission of other pathogens,
we are not aware of any health care facility that conducted an epide-
miologic look-back study of improperly reprocessed semicritical
medical devices (such as endoscopes) that assessed other pathogens
such as multidrug resistant Enterobacteriaceae or C difficile. Large-
scale epidemiologic look-back investigations of improperly reproc-
essed semicritical instruments (ie, GI endoscopes) for transmission of
BBPs have been conducted.6,59,60 In 1 investigation involving endo-
scopes in a nonhospital endoscopy clinic’s endoscope reprocessing
failures were not associated with an increased risk of BBP among
individuals tested.59 In another study involving almost 10,000 per-
sons tested for BBPs, the investigation revealed that exposure to
improperly reprocessed ear-nose-throat endoscopes did not result in
viral transmission in those patients who had genetic analysis per-
formed. Any potential transmission of BBP from colonoscopy remains
unknown because case/proximate patient testing could not be
performed.60
In addition, some health care facilities have considered evaluating
medical charts for evidence of risks or transmission of infection
among a certain population. The weakness of such an evaluation is
the absence of comparator data. That is, let us say you recognize non-
compliance with reprocessing urologic instruments and you look for
E coli in patients undergoing cystoscopies in an outpatient urology
office. Certainly, you will find a percentage (eg, 10%) of patients
undergoing cystoscopy with E coli in the urinary tract. Unfortunately,
you do not have a control population to compare your E coli fre-
quency in the urology clinic. The control population could be a group
of persons that underwent cystoscopies in an outpatient urology
clinic that reprocessed the endoscope in complete compliance with
the professional organization guidelines and manufacturer’s
IFU. Additionally, to compare the numbers between the 2 outpatient
urology clinics, the facilities would have to use the same surveillance
methodology, and identify methods to risk adjust the population
studied as there are many risk factors for E coli in the urine such as
older age, female sex, urinary catheterization, enlarged prostate, dia-
betes, not receiving antibiotics, malnutrition, et cetera. Therefore, the
question you must consider before beginning a chart review is how
the data will help you make a decision as you will likely find persons
with any outcome you consider (eg, HCV prevalence in US population
is 1.3%, HBV is 0.4%, and HIV is 0.3%). If you decide to do a chart
review, you will need to consider the surveillance method, the out-
come indicator to monitor, the time period for observation and
benchmarking, and comparator data. Of course, a chart review would
be unlikely to completely identify all persons infected (eg, HCV) or
colonized (eg, E coli in the urine) because testing asymptomatic
patients for colonization or infection is rarely indicated. Active sur-
veillance for such patients would be both logistically difficult and
expensive.
REPROCESSING SEMICRITICAL ITEMS
Reprocessing of GI endoscopes and bronchoscopes
More health care−associated outbreaks (>130 outbreaks) and
patient exposures have been linked to contaminated GI endoscopes
and bronchoscopes than to any other reusable medical device.7,8
Because the risk of transmission via GI endoscopes and broncho-
scopes will be reviewed in another article in this journal,61 the reason
for reprocessing failure will only be briefly discussed. There are at
least 2 (and probably 3) reasons for this reprocessing failure and why
outbreaks continue to occur.23 First, studies have shown that the
internal channel of GI endoscopes, including duodenoscopes, may
contain 107-10 (7-10-log10) enteric microorganisms.30,31 Investigations
have demonstrated that the cleaning step in endoscope reprocessing
results in a 2-6-log10 reduction of microbes and the HLD step results in
another 4-6-log10 reduction of mycobacteria for a total 6-12-log10
reduction of microbes.30−32 Thus, the margin of safety associated with
cleaning and HLD of GI endoscopes is minimal or nonexistent (level of
contamination: 4-log10 or 10,000 microbes [maximum contamination,
minimal cleaning/HLD] to −5-log10 [minimum contamination, maxi-
mum cleaning/HLD]). Therefore, any deviation from proper reprocess-
ing (such as crevices that harbor microorganisms associated with the
elevator channel) could lead to failure to eliminate contamination with
a possibility of subsequent patient-to-patient transmission. This low (or
nonexistent) margin of safety associated with endoscope reprocessing
compares to the 17-log10 margin of safety associated with cleaning and
sterilization of surgical instruments.23
Second, GI endoscopes not only have heavy microbial contamina-
tion (107-1010 bacteria) but they are complex with long, narrow
channels; right angle turns; and difficult to clean and disinfect com-
ponents (eg, elevator channel). The elevator channel in duodeno-
scopes is unique to side-viewing endoscopes. It has a separate
channel and provides orientation of catheters, guide-wires and acces-
sories into the endoscopic visual field.23 This channel is complex in
design and has crevices that are difficult to access with a cleaning
brush and may impede effective reprocessing.62 Based on this and
other recent studies, it is likely that MDROs are acting as a “marker”
or “indicator” organism for ineffective reprocessing of the complex
design of duodenoscopes, which is an infectious risk to patients.
Third, biofilms could impact endoscope reprocessing failure and
continued endoscope-related outbreaks.63 Biofilms are multilayered
bacteria plus exopolysaccharides that cements cells to surfaces. They
develop in a wet environment. If reprocessing is performed promptly
after use and the endoscope is dry the opportunity for biofilm forma-
tion is minimal.64,65 However, the formation of endoscopic biofilm
during clinical practice may be related to reuse of reprocessing meth-
ods such as reuse of detergent, manual cleaning, and incomplete dry-
ing.66 Ideally, reprocessing should be initiated within 1 hour of use;
however, there are no evidence-based guidelines on delayed endo-
scope reprocessing.67 It is unclear, but possible, that biofilms contrib-
ute to failure of endoscope reprocessing.
Infection preventionists should ensure that institutional policies
are consistent with national guidelines17,25 and manufacturers’
instructions-for-use, and conduct infection control rounds periodi-
cally (eg, at least annually) in areas where endoscopes and other
semicritical items are reprocessed to make certain there is compli-
ance with policy. Based on the infection data and risks, the transition
to sterilization of duodenoscopes was recommended by an FDA Panel
in May 2015. Technologies to allow this change to occur are being
developed68 and FDA-cleared and should be used when acceptable in
terms of sterilization performance, scope performance (for disposable
scopes), cost, throughput, and compatibility of materials (eg, adhe-
sives) to sterilization technology. Device and sterilization manufac-
turers, regulatory agencies, GI physicians, inpatient and outpatient
endoscope reprocessing centers as well as professional organizations
must reach a general agreement regarding the need for sterilization
and the willingness to replace existing disinfection technologies. This
transition will occur when we put “the needs of the patient first” and
offer every patient an endoscope that is sterile, and thus, devoid of
potential pathogens.39Nasal endoscopy
There are several types of scopes that are used to examine the
nose and throat (eg, nasopharyngoscope, rhinolaryngoscopes).
Because they become contaminated during use, there is a risk of
transmission of infection between patients. Flexible nasopharyngo-
scopy is a valuable tool enabling easy visualization of the upper aero-
digestive tract. In the United States, 3 techniques are available to
reprocess nasopharyngoscopes: manual HLD; use of an automated
endoscope reprocessor; and use of a disposable sheath with low-level
disinfection.17,68−70 However, because sheaths/condoms/covers may
have tears or breaks that compromise their integrity there was hesi-
tation to allow the use of a sheath to alter the recommendation of
HLD. There are now 2 peer-reviewed publications that validate the
integrity of the sheath with nasopharyngoscopes along with low-
level disinfection.71,72
One study showed that the use of a high quality, snugly fitting,
sterile, disposable polyurethane sheath on nasopharyngoscopes
during a clinical examination, combined with enzymatic detergent
cleaning and disinfection with 70% ethanol, provided a reliably
decontaminated, patient-ready instrument, which eliminated the
need for HLD of nasopharyngoscopes.71 Another study found that
the contamination rate on nasopharyngolaryngoscope (NPL) with
the sheath alone was similar to the contamination rate with the
high-level disinfected scope. The authors concluded that using the
individually packaged, disposable, sterile sheath on an NPL prevented
microbes from adhering to the shaft of the scope, thus providing a
safe method of avoiding the transmission of infection from 1 patient
to the next patient when using an NPL successively in multiple
patients in an otolaryngology clinic.72 These 2 studies corroborate the
integrity of the sterile polyurethane sheaths used with nasophar-
yngoscopes, this practice (use of a high-quality, snugly fitting, sterile,
disposable sheath on a nasopharyngoscope during a clinical examina-
tion, combined with enzymatic detergent cleaning and disinfection
with 70% ethanol) can provide a reliably decontaminated, patient-
ready instrument and may be an option to HLD. Thus, we believe that
with this specific sheath and this device (ie, nasopharyngoscope), this
practice of using this sheath plus cleaning plus alcohol may be an
option to HLD.Applanation tonometers
Applanation tonometers are a possible vector for the transmission
of infectious disease and outbreaks of epidemic keratoconjunctivitis
(caused by adenovirus),41,42 and have been related to incompletely
disinfected tonometers.22,41,42 In view of the potential for transmis-
sion of viruses (eg, herpes simplex virus, adenovirus type 8, or HIV)73
by tonometer tips, the CDC recommended74 that the tonometer tips
be wiped clean and disinfected for 5-10 minutes with either 3%
hydrogen peroxide, 5,000 ppm chlorine, 70% ethyl alcohol, or 70% iso-
propyl alcohol. However, data suggest that 3% hydrogen peroxide and
70% isopropyl alcohol are not effective against adenovirus capable of
causing epidemic keratoconjunctivitis and similar viruses and should
not be used for disinfecting applanation tonometers.75−77 For this
reason, the CDC guideline now recommends to wipe clean tonometer
tips and then disinfect them by immersing for 5-10 minutes in either
5,000 ppm chlorine or 70% ethyl alcohol.17,74−77 Structural damage to
Schiotz tonometers has been observed with a 1:10 sodium hypochlo-
rite (5,000 ppm chlorine) and 3% hydrogen peroxide.78 After disinfec-
tion, the tonometer should be thoroughly rinsed in tap water and air-
dried before use. We believe that wiping the tonometer tips with a
70% isopropyl alcohol wipe is insufficient to prevent patient-to-
patient transmission considering that 2 reports have found that disin-
fection of pneumotonometer tips between uses with a 70% isopropyl
alcohol wipe contributed to outbreaks of epidemic keratoconjunctivi-
tis caused by adenovirus type 8.79,80
Of course, intraocular instruments must be cleaned and sterilized
between patients. Eye instruments are very delicate and require spe-
cial handling to prevent damage. Recommended practices are derived
from evidence-based recommendations for cleaning and sterilizing
all surgical instruments in general, from outbreaks of toxic anterior
segment syndrome, and from manufacturers’ IFU.81 Toxic anterior
segment syndrome is an acute severe inflammatory reaction of the
anterior chamber of the eye to a toxic contaminant (eg, detergent res-
idues) introduced into the anterior chamber during intraocular
surgery.81
Endocavitary probes (vaginal probes)
Vaginal probes are used in sonographic scanning. A vaginal probe
and all endocavitary probes without a probe cover are semicritical
devices as they have direct contact with mucous membranes (eg,
vagina, rectum, and pharynx). Although one could argue that the use
of the probe cover changes the category, the CDC guideline for disin-
fection and sterilization17 proposes that a new condom/probe cover
should be used to cover the probe for each patient and because con-
doms/probe covers may fail,82−86 HLD of the probe also should be
performed.17,87 The relevance of this recommendation is reinforced
with the findings that sterile transvaginal ultrasound probe covers
have a very high rate of perforations even before use (0%, 25%, and
65% perforations from 3 suppliers).85 After oocyte retrieval use,
Hignett and Claman85 found a very high rate of perforations in used
endovaginal probe covers from 2 suppliers (75% and 81%), whereas
Amis et al88 and Milki and Fisch82 demonstrated a lower rate of perfo-
rations after use of condoms (0.9% and 2.0%, respectively). Rooks
et al89 found that condoms were superior to commercially available
probe covers for covering the ultrasound probe (1.7% for condoms vs
8.3% leakage for probe covers). These studies underscore the need for
HLD of endocavitary probes between examinations. Although most
ultrasound manufacturers have recommend the use of 2% glutaralde-
hyde for HLD of contaminated transvaginal transducers, the use of
this agent has been questioned90 because it may shorten the life of
the transducer and may have toxic effects on the gametes and
embryos.91 Another probe disinfection method that uses a UV-C
chamber has been evaluated and is used in Europe and Canada but is
not yet FDA-cleared for use in the United States.86,92
HLD with an FDA-cleared high-level disinfectant (eg, accelerated
hydrogen peroxide) that is nontoxic to staff, patients, probes, and
retrieved cells should be used until the effectiveness of alternative
procedures against microbes of importance at the cavitary site is
demonstrated by well-designed experimental scientific studies. Other
probes such as rectal and cryosurgical probes/devices should also be
subjected to HLD between patients.
Cryosurgery is the use of freezing temperatures to elicit a specific
response in tissue (eg, inflammatory response with minor freezing).
Some cryosurgical probes (eg, used in prostate cancer) are not fully
immersible. When reprocessing these probes, the tip of the probe
should be immersed in a high-level disinfectant for the appropriate
time (eg, 20 minutes exposure with 2% glutaraldehyde) and any other
portion of the probe that could have mucous membrane contact
should be disinfected by immersion or wrapping with a cloth soaked
in a high-level disinfectant to allow the recommended contact time.
After disinfection, the probe should be rinsed with tap water and
dried before use. Health care facilities that use nonimmersible probes
should replace them as soon as possible with fully immersible
probes.
As with other HLD procedures, proper cleaning of probes is neces-
sary to ensure the success of the subsequent disinfection.93 Muradali
et al94 demonstrated a reduction of vegetative bacteria inoculated onvaginal ultrasound probes when the probes were cleaned with a
towel. No information is available on either the level of contamina-
tion of such probes by potential viral pathogens, such as HBV and
human papillomavirus (HPV),95 or their removal by cleaning (such as
with a towel). Because these pathogens may be present in vaginal
and rectal secretions and contaminate probes during use, HLD of the
probes after such use is recommended.
Concerning low-level disinfection of vaginal probes, M’Zali
et al96 demonstrated the persistence of microbial contamination
on transvaginal ultrasound probes after low-level disinfection
with a quaternary ammonium compound and chlorhexidine gluco-
nate. Meyers et al97 demonstrated that some high-level disinfectants
(eg, glutaraldehyde, OPA) may not be effective against HPV but this
requires corroboration. At the present time, we do not believe that
this report should result in an alteration of current cleaning/disinfec-
tion recommendations.
The CDC guideline for disinfection and sterilization states that
even if probe covers have been used, clean and high-level disinfect
the semicritical devices such as rectal probes, vaginal probes, and
cryosurgical probes with a product that is not toxic to staff, patients,
probes, and retrieved germ cells (if applicable). Use a high-level disin-
fectant at the FDA-cleared exposure time unless scientific studies
and guidelines recommend an alternative time and temperature (eg,
glutaraldehyde at 20 minutes, 20°C).17,25 When probe covers are
available, use a probe cover or condom to reduce the level of micro-
bial contamination. Do not use a lower category of disinfection (eg,
low-level disinfection) or cease to follow the appropriate disinfectant
recommendations when using probe covers because these sheaths
and condoms may fail (see exception for nasopharyngoscopes and
one tested sheath described earlier). After HLD, rinse all items.
Ultrasound transducer disinfection for assessment and insert of
peripheral and central catheters
At present, there is no consistency in the practice of cleaning/dis-
infecting ultrasound probes used for the assessment and insertion of
peripheral and central catheters.98 This begs the question: do ultra-
sound transducers used for placing peripheral or central venous
access devices require HLD or sterilization? A recent publication has
interpreted the CDC and the American Institute for Ultrasound in
Medicine guidelines to recommend that the probe used for ultra-
sound-guided central venous catheter insertion be either sterilized or
HLD and used with a sterile sheath and sterile gel.98 The same article
recommended that the probe used to scan across unhealthy skin
should be high-level disinfected and used with a clean sheath and
clean gel.98 The American Institute for Ultrasound in Medicine and
Association of Vascular Access guidelines are similar and recommend
that all transducers used for peripheral or central venous access
device insertion should undergo, at a minimum, low-level disinfec-
tion (ie, step 1-clean, step 2-low-level disinfect) and be used in con-
junction with a single-use sterile probe cover.99,100 Should such a
probe on occasion become contaminated with blood or other poten-
tially infectious material, appropriate cleaning and low-level disinfec-
tion would eliminate the key BBPs (ie, HIV, HBV, and HCV).
Transrectal ultrasound-guided prostate biopsy probes
Transrectal ultrasound-guided prostate biopsies are among the
most common outpatient diagnostic procedures performed in urol-
ogy practice, to evaluate patients for prostate cancer after an elevated
prostate-specific antigen level or abnormal digital rectal examination
findings.40 It involves obtaining multiple prostate tissue cores by
passing a disposable biopsy needle through a needle guide under
ultrasound guidance. All prostatic biopsy procedures result in con-
tamination of the probe with blood or feces. During this procedure,
the transducer assembly is generally covered with a barrier sheath.101
Breaches in the reprocessing of prostate biopsy probes can pose a risk
of disease transmission.40,102
Disinfection or sterilization of ultrasound transducer components
is based on the function or use of each component. Considering that
the biopsy needle penetrates sterile tissue for biopsy, it should be
sterile. Ideally, the needle guide should be sterilized between patient
uses. However, if this is not possible (ie, clinic does not have a steril-
izer as biopsy needles are likely purchased as single-use sterile devi-
ces) then HLD after disassembly and cleaning is acceptable as it has
contact with mucous membranes but not sterile tissue. The FDA
alert101 and a CDC article40 recommends that the needle guide be
sterilized as the biopsy needle contacts the needle guide before it
penetrates sterile tissue. This recommendation is inconsistent with
current recommendation for the disinfection of GI endoscopes. It is
currently recommended that GI endoscopes be high-level disinfected
minimally but that medical devices that pass through the endoscope
and enter sterile tissue (eg, biopsy forceps) be sterilized.17,25 There is
no recommendation that the lumen or channel through which they
pass should also be sterilized. One possible explanation for the incon-
sistency in this FDA recommendation is that the GI endoscopes can
only be high-level disinfected as there is no practical way to sterilize
them, whereas the reusable needle guide for prostate probes can be
sterilized (written communication, MJ Arduino, August 2006).
Although a barrier sheath is used on the transducer assembly during
the biopsy procedure, the sheath is compromised by the penetration
of the needle.101 Although prostate probes and other endocavitary
probes are often covered with a disposable sheath or condom,101
such covers do not adequately protect the probe from microbial con-
tamination because of leakage (9%),103 and thus, the use of a cover
does not alter the requirement for HLD minimally.17 FDA specifies the
use of a sterile barrier sheath in their recommendation for reprocess-
ing reusable ultrasound transducer assemblies.101 It is appropriate to
use a sterile barrier sheath when an ultrasound probe is entering a
sterile body cavity, but when the probe is entering the rectum the
need for a sterile barrier sheath is unclear.
All semicritical and critical medical devices must be thoroughly
cleaned with enzymatic or nonenzymatic detergents before it is sub-
jected to a HLD or sterilization process, respectively. Brushes should
be used, when possible, to effectively clean the transducer assem-
blies, especially the lumens. One investigation shows that the needle
guide and prostate probe can be effectively disinfected with glutaral-
dehyde, but the needle guide must be disassembled from the trans-
ducer assembly.20
The FDA issued a Public Health Notification in June 2006, because
of follow-up to the Department of Veterans Affairs, Veterans Health
Administration Patient Safety Alert related to a company’s ultrasound
transducer assemblies. During patient safety rounds, the lumen of a
needle guide of an ultrasound transducer assembly was found to
be soiled. The FDA guidance consisted of several steps (see http://
www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealth
Notifications/ucm062086.htm for complete method recommended
by the FDA). We have evaluated the FDA steps and suggest some
modifications.11 Do not reuse items labeled for single use (eg, single-
use biopsy needles, needle guides). Additional recommendations
may be available in the operator’s manuals or user guides. It is impor-
tant that these recommendations be consistent with disinfection and
sterilization guidelines/principles or that these recommendations
have been validated by appropriate scientific studies. Do not use any
disinfectant that can cause irreparable damage to the materials used
to construct the probe. For example, if an alcohol rinse is not compati-
ble with the probe, rinse with sterile water (not filtered water, or tap
water), and do not rinse with alcohol. These recommendations could
be adapted to all ultrasonic prostate probes to include those with an
external needle guide attachment.TEE probes
TEE probes are another semicritical device that has a potential for
infection between sequential patients. Five outbreaks have been asso-
ciated with TEE probes used in cardiovascular surgical opera-
tions.51,54−57 In 2 outbreaks, a defect in the probe was identified.54,55
Once the damaged TEE probes were removed from use, no additional
cases were identified in the cardiac surgery patients. The defect pre-
sumably prevented exposure of the bacteria to the high-level disin-
fectant. To ensure proper HLD, health care facilities should ensure the
probes are not damaged and comply with recommendations from
professional organizations and the manufacturer. The basic principle
for successful reprocessing of the probe involves: clean the probe
shaft and probe tip (via immersion or wiped with a wipe moistened
with detergent/enzymatic) to remove gross contamination (a second
wipe is used to wipe nonimmersible parts higher up including the
handle); inspect to ensure no structural damage; disinfect with a
high-level disinfectant (distal tip and flexible shaft are immersed in
the high-level disinfectant, wipe the higher portions with a compati-
ble disinfectant); thoroughly rinse; and dry before storage.104 Protec-
tive sheaths are an additional physical barrier to infection and probe
damage; however, they do not remove the possibility of infection as
sheaths do not cover all of the TEE probes and the sheaths are subject
to perforations.105 Strict adherence to manufacturers’ instructions
when using chemical disinfectants such as OPA for TEE probe reproc-
essing are required to avoid aerodigestive tract chemical injury.106
TEE probes require HLD regardless of whether a sheath is used. Many
hospitals use a vapor control system that reduces exposure of staff to
toxic vapors and damage to the instrument (eg, wall rack holder such
as glutaraldehyde user station). Follow the manufacturer’s instruc-
tions and/or professional organizational guidelines for soak times and
cleaners.
Infrared coagulation
Infrared coagulation is a widely used method for treating hemor-
rhoids. The procedure involves applying infrared light to compress
and seal hemorrhoid veins. The manufacturer of the device sells a
sterile disposable sheath and states removing and soaking light
guides between procedures is no longer required. The manufacturer
also states that the light guide is damaged by immersion in a disinfec-
tant as the light guide is not sealed at the end and the disinfectant
gets between the quartz glass and the covering.
As mentioned, the CDC guideline recommends immersion for
reprocessing endocavitary probes with covers because integrity of
the cover is compromised. Because the light guide cannot be
immersed, we investigated an alternative procedure. This procedure
involved wiping the probe for 2 minutes with a 1:10 bleach (5,000
ppm) and after that was completed, wiping the probe with sterile
water and letting the probe air dry. This procedure has been found
effective in eliminating »7 log10 reduction (7.8£ 106) of Mycobacte-
rium terrae and is used at our hospital for decontamination of the
sheathed device after use.107
Laryngoscopes
Laryngoscopes are a potential source of infection108 and have been
associated with at least 2 outbreaks.43−45 Laryngoscopes are routinely
used to view the vocal cords and larynx and for airway management.
It typically consists of a blade that connects to a handle, which usually
contains 2 batteries that powers the light source. Limited guidelines
are available for reprocessing laryngoscope blades and handles and
hospital practices vary.45,109,110 For example, some guidelines recom-
mend and hospitals use low-level disinfection of the handle as it does
not have direct contact with a mucous membrane, whereas others
recommend that the handle be high-level disinfected to prevent dis-
ease transmission. Although blades have been linked to health care
−associated infections, handles have not been directly linked to
health care−associated infections. However, reports of contamination
with blood (40% of the handles positive for occult blood) and poten-
tially pathogenic microorganisms (86% of the handles deemed “ready
for patient use” positive including Staphylococcus aureus, Acineto-
bacter) suggest its potential45,111−113 and the blade and handle func-
tion together. For this reason, it is ideal that the blades and handles
be high-level disinfected or sterilized, even if a protective barrier or
sheath is used during the procedure. In 2007, the State of California
required that both blades and handles be HLD or sterilized. At Univer-
sity of North Carolina Hospitals we were sterilizing the blades and
handles (ie, blades via hydrogen peroxide gas plasma, handle [with-
out batteries] by steam), but we have transitioned to sterile, dispos-
able blades and handles. This practice saves time, eliminates the risk
of cross contamination and reduces the likelihood on nonperforming
equipment. A few specialty areas continue to sterilize the blade and
handle. Per the Joint Commission, the laryngoscope blade and handle
must be packaged in a way that prevents recontamination after proc-
essing. Examples of compliant storage include, but are not limited to,
a peel pack poststerilization (long-term storage) or wrapping in a
sterile towel (short-term storage).
Advances in video-technology have led to the development of
video laryngoscopes such as the GlideScope (Verathon, Bothell, MA)
and McGrath video laryngoscopes (Medtronic, Minneapolis, MN).
These new intubation devices assist in difficult airway management.
The manufacturer’s IFU should be followed for reprocessing the reus-
able component of these scopes.
Other channeled endoscopes (cystoscopes, ureteroscopes,
hysteroscopes)
In the United States, it is estimated that over 4 million cystoscop-
ies are performed each year. Cystoscopy is a diagnostic procedure
that uses an endoscope especially designed to examine the bladder,
lower urinary tract, and prostate gland or is used to collect urine sam-
ples, perform biopsies, and remove small stones. A flexible or rigid
scope can be used to carry out the procedure. Considering that the
procedure involves a medical device in contact with the patient’s
mucous membranes, it is considered a semicritical device that must
minimally be high-level disinfected. Failure to properly high-level
disinfect or sterilize semicritical equipment can lead to contamina-
tion114 and transmission of infection.46
A recent study demonstrated how important it is to perfuse the
high-level disinfectant into the channel of cystoscopes and other
channeled scopes (eg, hysteroscopes, ureteroscopes). This study dem-
onstrated that disinfection (ie, a reduction in bacterial load of >7-
log10 CFU) did not occur unless the channel was actively perfused
with the glutaraldehyde. In fact, failure to perfuse the channel led to
only minimal, if any, reduction in bacterial contamination. However,
complete inactivation of 108 CFU of both vancomycin-resistant
Enterococcus and CRE was achieved when the channel was actively
perfused. It appears that no high-level disinfectant entered the chan-
nel unless it was actively perfused via a syringe, as the level of micro-
bial contamination was not reduced by immersion. This occurs
because the air pressure in the channel is stronger than the fluid pres-
sure at the fluid-air interface. Recommendations are provided for cys-
toscope HLD and include actively perfusing the device while
immersed in the high-level disinfectant.115
Cystoscopes have also been implicated as the source of infection
to multiple patients when incorrect disinfection methods were iden-
tified.46 This may, in part, be related to the lack of awareness of rec-
ommendations specifically for disinfecting cystoscopes116 or failing
to follow the manufacturer’s instructions, which specify perfusing thelumen using a high-level disinfectant. Unfortunately, some cysto-
scope reprocessing recommendations published in the literature are
incorrect. For example, authors have recommended complete immer-
sion of the cystoscope into the high-level disinfectant but did not
mention perfusion of the high-level disinfectant into the channel.46
We suggest following published recommendations11 and those of the
American Urological Association116 until evidence-based guidelines
have been published. Anaphylactic reactions have been reported in
patients with bladder cancer who underwent repeated cystoscopy
using scopes that were HLD with OPA, and thus, OPA is contraindi-
cated in patients with a history of bladder cancer.116
CURRENT ISSUES
Hydrogen peroxide mist system for probes
An alternative procedure for disinfecting the endocavitary and sur-
face probes is a hydrogen peroxide mist system, which uses 35% hydro-
gen peroxide at 56°C with the probe reaching no more than 40°C (ie,
Trophon). In one study, the results demonstrated complete inactivation
(>6-log10 reduction) of vancomycin-resistant Enterococcus and a CRE-
Klebsiella pneumoniae strain in both the presence and absence of 5%
fetal calf serum (FCS). The Trophon EPR system (Nanosonics, Indianapo-
lis, IN) showed good, but not complete, inactivation of M terrae (5.2-
log10 reduction for M terrae with FCS; 4.6-log10 reduction for M terrae
without FCS) and C difficile spores (5.1-log10 reduction for C difficile
spores with FCS; 6.2-log10 reduction for C difficile spores without
FCS).117 Other data have demonstrated the activity of Trophon to inacti-
vate HPV118 and other pathogens (eg, bacteria, mycobacteria, viruses)
including a >6-log10 reduction ofM terrae and C difficile spores in carrier
tests and a >6-log10 reduction in M terrae on inoculated ultrasound
probes.119 These results differ slightly from those presented earlier, pre-
sumably because of the differences in testing methodology. In our
study, only the probe devices were inoculated (carriers of different
materials were not tested) and for recovery of bacteria on the probe,
the probes were immersed in media (not swabbed, which would likely
result in lower recovery).117 The Trophon system processes the portion
of the probe that has mucous membrane contact but also the handle of
an endocavitary probe, which may be contaminated, and it is an alter-
native to high-level chemical disinfection for ultrasound probes.
Storage of semicritical items
In 2011, the Joint Commission recommended that laryngoscope
blades be packaged in a way that prevents recontamination. Examples
of compliant storage include, but are not limited to, a peel pouch or a
closed plastic bag. Examples of noncompliant storage would include
unwrapped blades in an anesthesia drawer as well as an unwrapped
blade on top of or within a code cart. The packaging not only prevents
recontamination but also distinguishes a processed from a nonpro-
cessed semicritical item such as a speculum, laryngoscope blade, or
endoscope. The use of a tagging system that separates processed from
nonprocessed items minimizes the use of a semicritical item that has
not been reprocessed and prevents patient exposures to a nonrepro-
cessed semicritical item.6 This could involve a tag (eg, green tag = patient
ready, red tag = requires reprocessing) for GI endoscopes or a plastic
sheath or plastic-paper peel pouch (eg, endocavitary probes). Ideally,
hospitals and ambulatory care facilities (as appropriate)24 should
develop a strategy (eg, tagging, storage covers for patient-ready devices)
that prevents patient exposures to contaminated devices.
HPV
HPV is an extremely common sexually-acquired infection and is the
most important cause of cervical cancer. An article in 2014
demonstrated that the FDA-cleared high-level disinfectants (ie, glutar-
aldehyde, OPA) tested did not inactivate the HPV, a nonenveloped
virus.97 These findings are inconsistent with many articles in the peer-
reviewed literature that demonstrates that high-level disinfectants
such as OPA and glutaraldehyde inactivate nonenveloped viruses such
as hepatitis A virus, polio, adenovirus, norovirus, et cetera.17 Because
the HLD are commonly used to disinfect endocavitary probes (eg, vagi-
nal probes, rectal probes), there is an urgency to corroborate these data.
In a conversation with CDC staff regarding this issue, it was determined
hospitals should continue to use the FDA-cleared high-level disinfec-
tants consistent with the manufacturers’ instructions until the data can
be corroborated. Data have demonstrated the activity of a hydrogen
peroxide mist device118 as well as a UV-C unit120 to inactivate the HPV.
To reduce the risk of transmission of HPV via transvaginal ultrasound,
Combs and Fishman121 recommended disinfection of the transvaginal
probe with the hydrogen peroxide mist device and covering them with
a condoms during examinations. In October 2018, an abstract by Ozbun
et al was presented at the 32nd International Papillomavirus Conference
in Australia, which demonstrated that HPV was inactivated by a variety
of disinfectants including OPA.Do not reuse single-use devices
The Department of Justice and the FDA have joined forces in prose-
cuting health care providers that reuse single-use devices. For example,
a physician was criminally prosecuted for reusing needle guides meant
for single use during prostate procedures. These prosecutions are based
on conspiracy to commit adulteration and Medicare fraud. Third party
reprocessing is allowed by the FDA when the reprocessor is considered
the device manufacturer as defined under 21 CFR Part 820.CONCLUSIONS
Strict adherence to current guidelines are required for semicritical
items, as more outbreaks have been linked to inadequately cleaned
or disinfected semicritical items such as endoscopes undergoing HLD
than any other reusable medical device.References
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